Slide 1: Thyrocare cover and exchange filing letter
Thyrocare Think Thyroid. Think Thyrocare. May 20, 2019 The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sirs, Sub: Presentation on Annual Results fo
Slide 2: Financial results for the quarter and year ended 31.03.2019
Thyrocare Technologies Limited Financial results for the quarter and year ended 31.03.2019 18-05-2019
Slide 3: Disclaimer
Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informatio
Slide 4: Summary of quarterly and annual financial performance
Summary of quarterly and annual financial performance 18-05-2019
Slide 5: Standalone financials Thyrocare
Standalone financials Thyrocare Thyrocare (Rs. in crore, except per share data) Particulars Quarter Endded Qtr. YOY Year Ended Year YOY 31 March 31 December 31 March (%) 31 March 31 March (%) 2019 2018 2018 2019 2018 Revenue from operations 97.29 88.12 90.03 8 370.28 331.79 12 Cost of Materials cons
Slide 6: Standalone financials Nueclear
Standalone financials Nueclear Nueclear (Rs. in crore, except per share data) Particulars Quarter Endded Qtr. YOY Year Ended Year YOY 31 March 31 December 31 March (%) 31 March 31 March (%) 2019 2018 2018 2019 2018 Revenue from operations 8.33 8.16 6.62 26 32.64 24.52 33 Cost of Materials consumed/
Slide 7: Consolidated financials Thyrocare
Consolidated financials Thyrocare Thyrocare [Consolidated] (Rs. in crore, except per share data) Particulars Quarter Endded Qtr. YOY Year Ended Year YOY 31 March 31 December 31 March (%) 31 March 31 March (%) 2019 2018 2018 2019 2018 Revenue from operations 105.59 96.29 96.66 9 402.91 356.32 13 Cost
Slide 8: Annual Financial Performance
Annual Financial Performance 18-05-2019
Slide 9: Thyrocare - Revenue, number of samples, tests
Thyrocare - Revenue, number of samples, tests INR in crore Growth '31 March 2015 '31 March 2016 '31 March 2017 31 March 2018 31 March 2019 YoY CAGR Revenue from operations (in crore) 180.08 225.42 285.98 331.79 370.28 12% 22% Number of samples (in thousands) 9,093.70 11,596.70 14,284.39 16,328.42 18
Slide 10: Nueclear - Revenue, number of scans
Nueclear - Revenue, number of scans INR in crore Growth '31 March 2015 '31 March 2016 '31 March 2017 31 March 2018 31 March 2019 YoY CAGR Revenue from operations (in crore) 9.65 15.55 18.30 24.52 32.64 33% 70% Revenue from PETCT scans 9.65 15.55 18.30 22.71 29.65 31% 67% Number of PETCT scans 11115
Slide 11: Quarterly Financial Performance
Quarterly Financial Performance 18-05-2019
Slide 12: Key trends - Thyrocare
Key trends - Thyrocare Revenue from Number of tests Number of samples operations (in crore) (in thousands) (in thousands) 8% 97.29 12% 90.03 21% For the entire financial year, Pathology business grew by 12% with underlying sample growth at 15% and investigations growth at 20%, this after 4861.823 28
Slide 13: Key trends - Nueclear
Key trends - Nueclear Revenue from Number of operations (in crore) PETCT scans 26% 8.33 7337 26% For the entire financial year, Radiology business 6.62 5824 grew by 33% and number of PETCT scans reported grew at 32%, this despite suspension of operations at Jaipur and Raipur for part of the financia
Slide 14: Thank You.
Thyrocare’ Think Thyroid. Think Thyrocare. Thank You. 18-05-2019